
Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma
Severe and fatal infections typically occurred early after CAR T-cell therapy ciltacabtagene-autoleucel (cilta-cel; Carvykti) infusion or standard-of-care (SOC) treatment initiation in patients with multiple myeloma, with increased risk within the first …